Antidiabetic Biosimilars Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Insulin, Biguanides, Sulfonyl Ureas, Thiazolidinediones, Di Peptidyl Peptidase (DPP)-IV Inhibitors, ?-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others),By Disease Type (Type-I Diabetes, Type-II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Region Forecast 2020-2031

Antidiabetic Biosimilars Market size was valued at US$ x million in 2024 and is expected to reach US$ x million by 2031, growing at a significant CAGR of x% from 2025-2031. Biosimilars are biological substances that are highly similar to biologics but not identical to patented biological molecules. These are manufactured after the patent expiration of the original products. Anti-diabetic biosimilars help to control the blood glucose levels in diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonylureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others.

These are cost-effective molecules with similar potency and efficiency compared with reference biological molecules. Antidiabetics help diabetic people control their blood glucose levels. Biguanides, thiazolidinediones, DPP-IV inhibitors, -glucosidase inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists like exenatide are examples of antidiabetics. A biosimilar product is a biological product that has been approved by the FDA because it is very similar to an FDA-approved biological product called a reference product. To demonstrate that the biosimilar manufactured gives the same therapeutic benefit to patients as the reference medication, biosimilar manufacturers must generate data from lab testing and clinical testing.

Key Developments:

• In May 2017, Sanofi received Committee for Medicinal Products for Human Use (CHMP) recommendation for approval of Insulin Lispro Biosimilar